Keyword: Seattle Genetics
Big biopharmas may still turn to M&As, thanks to their cash power, restructuring plans and a now-or-never mentality, one group of analysts say.
Daiichi and AZ's Enhertu as well as and Astellas and Seattle Genetics' Padcev won FDA nods as China approved rivals to Prevnar and Gardasil.
Wednesday, the FDA approved Padcev, a first-of-its kind antibody-drug conjugate. The product targets Nectin-4, a protein on the surface of cells.
Amgen pays $2.7 billion for a 20.5% stake in BeiGene. AstraZeneca tightens its ties to China as China approves a controversial Alzheimer's drug.
Sanofi slims down in Japan. We examine Big Pharma CEOs' Chinese names. Positive data came out from Astellas, Eisai and Chi-Med at ESMO.
If Seattle Genetics' second-quarter earnings report is any indication, the company's lead product is finally living up to its potential.
In one ASCO surprise, the usual complaints about "too much advertising" were absent this year. In fact, attendees mostly shrugged.
The cancer world flocked to this weekend's ASCO meeting, traditionally the biggest oncology confab of the year. Here's your need-to-know.
Gearing up for the year's largest cancer confab, we break down the highlights to give you a glimpse of the studies we’re tracking, so you can follow along, too.
Now well on its way to becoming a multiproduct company, Seattle Genetics has decided the time is right to bring in its first chief commercial officer.